Figure 2.
Figure 2. Important transplant trials. CTX, cytoxan; CY, cyclophosphamide; G-CSF, granulocyte colony-stimulating factor; HDM, high-dose melphalan; MEL, melphalan; PBSC, peripheral blood stem cells; SCT, stem cell transplant; VCD, bortezomib-cyclophosphamide-dexamethasone; VMP, bortezomib-melphalan-prednisone; VRD, bortezomib-lenalidomide-dexamethasone.

Important transplant trials. CTX, cytoxan; CY, cyclophosphamide; G-CSF, granulocyte colony-stimulating factor; HDM, high-dose melphalan; MEL, melphalan; PBSC, peripheral blood stem cells; SCT, stem cell transplant; VCD, bortezomib-cyclophosphamide-dexamethasone; VMP, bortezomib-melphalan-prednisone; VRD, bortezomib-lenalidomide-dexamethasone.

Close Modal

or Create an Account

Close Modal
Close Modal